{
"id":"mk19_a_np_t24",
"number":24,
"bookId":"np",
"title":{
"__html":"Classification of Lupus Nephritis with Associated Presentation and Treatment Options"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3abd2d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 24. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_np_t24"
}
]
},
"Classification of Lupus Nephritis with Associated Presentation and Treatment Options"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d09ae",
"class":"col hd l",
"children":[
"ISN/RPS Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d12cf8",
"class":"col hd l",
"children":[
"Biopsy Findings"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7962dd",
"class":"col hd l",
"children":[
"Clinical Features"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd c",
"children":[
"Treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93d553",
"class":"col hd l",
"children":[
"Induction Phase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"463417",
"class":"col hd l",
"children":[
"Maintenance Phase"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dee19b",
"class":"cell txt l",
"children":[
"Class I: minimal mesangial LN"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ab6fe",
"class":"cell txt l",
"children":[
"No LM abnormalities; isolated mesangial IC deposits on IF and EM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6fa42",
"class":"cell txt l",
"children":[
"Normal urine or microscopic hematuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eee26",
"class":"cell txt l",
"children":[
"Conservative therapy (e.g., RAS blockade)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e681a3",
"class":"cell txt l",
"children":[
"Not applicable"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7bf8b",
"class":"cell txt l",
"children":[
"Class II: mesangial proliferative LN"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"239844",
"class":"cell txt l",
"children":[
"Mesangial hypercellularity or matrix expansion with mesangial IC deposits on IF and EM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5d54f",
"class":"cell txt l",
"children":[
"Microscopic hematuria and/or low-grade proteinuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eee26",
"class":"cell txt l",
"children":[
"Conservative therapy (e.g., RAS blockade)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e681a3",
"class":"cell txt l",
"children":[
"Not applicable"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b46dae",
"class":"cell txt l",
"children":[
"Class III: focal LN"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e9f47",
"class":"cell txt l",
"children":[
"<50% of glomeruli on LM display endocapillary and/or extracapillary proliferation; mesangial and focal subendothelial IC deposits on IF and EM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7820ba",
"class":"cell txt l",
"children":[
"Nephritic urine sediment and subnephrotic proteinuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e048f0",
"class":"cell txt l",
"children":[
"Pulse IV glucocorticoids followed by tapering doses of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"c33d48",
"class":"cell txt l",
"children":[
"IV cyclophosphamide"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea7c53",
"class":"cell txt l",
"children":[
"Lowest tolerable amount of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"beadbe",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil (tapered down assuming stable disease)"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"f01f22",
"class":"cell txt l",
"children":[
"Azathioprine (tapered down assuming stable disease)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eedd57",
"class":"cell txt l",
"children":[
"Class IV: diffuse LN"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7f2c8",
"class":"cell txt l",
"children":[
"â‰¥50% of glomeruli on LM display endocapillary and/or extracapillary proliferation; mesangial and diffuse subendothelial IC deposits on IF and EM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1718d5",
"class":"cell txt l",
"children":[
"Nephritic and nephrotic syndromes; hypertension; reduced kidney function"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e048f0",
"class":"cell txt l",
"children":[
"Pulse IV glucocorticoids followed by tapering doses of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"c33d48",
"class":"cell txt l",
"children":[
"IV cyclophosphamide"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea7c53",
"class":"cell txt l",
"children":[
"Lowest tolerable amount of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"beadbe",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil (tapered down assuming stable disease)"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"f01f22",
"class":"cell txt l",
"children":[
"Azathioprine (tapered down assuming stable disease)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e5ea4e",
"class":"cell txt l",
"children":[
"Class V: membranous LN",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f8149",
"class":"cell txt l",
"children":[
"Diffuse thickening of the glomerular capillary walls on LM with subepithelial IC deposits on IF and EM, with or without mesangial IC deposits"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e048f0",
"class":"cell txt l",
"children":[
"Pulse IV glucocorticoids followed by tapering doses of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"c33d48",
"class":"cell txt l",
"children":[
"IV cyclophosphamide"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"bae995",
"class":"cell txt l",
"children":[
"Calcineurin inhibitor (cyclosporine or tacrolimus)"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea7c53",
"class":"cell txt l",
"children":[
"Lowest tolerable amount of oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"006063",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"beadbe",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil (tapered down assuming stable disease)"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"f01f22",
"class":"cell txt l",
"children":[
"Azathioprine (tapered down assuming stable disease)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"928469",
"class":"cell txt l",
"children":[
"Class VI: advanced sclerosing LN"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8eab15",
"class":"cell txt l",
"children":[
">90% of glomeruli on LM are globally sclerosed with no residual activity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd396f",
"class":"cell txt l",
"children":[
"Advanced CKD or ESKD with varying degrees of hematuria and/or proteinuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8a1c9",
"class":"cell txt l",
"children":[
"Preparation for renal replacement therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e681a3",
"class":"cell txt l",
"children":[
"Not applicable"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CKD = chronic kidney disease; EM = electron microscopy; ESKD = end-stage kidney disease; IC = immune complex; IF = immunofluorescence; ISN/RPS = International Society of Nephrology/Renal Pathology Society; IV = intravenous; LM = light microscopy; LN = lupus nephritis; RAS = renin-angiotensin system."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Class V may coexist with class III or class IV, in which case both classes are diagnosed."
]
]
}